Natalia Andersen1,3, Tania Veuthey1,3, Gabriela Blanco1,3, Gustavo Silbestri2,4, Diego Rayes1,3 and María José De Rosa1,3
1 INIBIBB. CCT-CONICET.
2 INQUISUR. CCT-CONICET.
3 Departamento de Biología, Bioquímica y Farmacia, UNS. 4Departamento de Química, UNS
By using C. elegans, our work aimed to explore novel biological roles for imidazole-containing compounds. To this end, we have tested the in vivo anti-proteotoxic effects of imidazolium salts. Since neurodegenerative diseases have been largely linked to impaired antioxidant defense mechanisms, we focused on 1-Mesityl-3-(3-sulfonatopropyl) imidazolium (MSI), one of the imidazolium salts that we identified as capable of improving iron-induced oxidative stress resistance in wild-type animals. By combining mutant and gene expression analysis we have determined that this protective effect depends on the activation of the Heat Shock Transcription Factor (HSF-1), whereas it is independent of other canonical cytoprotective molecules such as abnormal Dauer Formation-16 (DAF-16/FOXO) and Skinhead-1 (SKN-1/Nrf2). To delve deeper into the biological roles of MSI, we analyzed the impact of this compound on previously established C. elegans models of protein aggregation. We found that MSI ameliorates β-amyloid-induced paralysis in worms expressing the pathological protein involved in Alzheimer’s Disease. Moreover, this compound also delays age-related locomotion decline in other proteotoxic C. elegans models, suggesting a broad protective effect.
Taken together, our results point to MSI as a promising anti-proteotoxic compound and provide proof of concept of the potential of imidazole derivatives in the development of novel therapies to retard age-related proteotoxic diseases.